The announcement. New Zealand is now the second country in the world, after Australia, to authorise MDMA for severe post-traumatic stress disorder. The trials behind it found up to 71.2% of patients no longer met the diagnostic criteria afterwards.
The fine print. Two named psychiatrists were approved, not the drug. MDMA remains an unapproved medicine. A course runs about NZ$45,000 and no public funding has been allocated. Australia, two years into the same policy, has treated 123 people.
New Zealand’s medicines regulator has cleared two psychiatrists to prescribe MDMA for severe post-traumatic stress disorder. Every outlet that covered it led with the trial success rates and the line about being second in the world after Australia, and not one of them checked what Australia’s identical decision has actually produced since 2023, or set that number beside the roughly NZ$45,000 a New Zealand patient will be asked to pay.
So here it is. By the end of December 2025, Australia’s scheme had treated 123 people.
You need both halves of that to understand what happened this week.
What Medsafe Actually Signed
Start with what the headlines get wrong. Medsafe did not approve a medicine. MDMA is an unapproved medicine in New Zealand today and it will still be one tomorrow.
What the regulator granted, as RNZ first reported, was individual authorisation to two named doctors: Gary Wynn in Wellington, who specialises in PTSD and trauma, and Tom Paterson in Auckland, whose field is addiction. They applied under regulation 22 of the Misuse of Drugs Regulations 1977, and they spent more than a year working through it. Any other psychiatrist in the country who wants to do this starts that process from the beginning.
The clinical conditions are tight, and sensible. Patients must be over 18 and assessed first. Dosing happens at the prescriber’s clinic, wrapped in psychotherapy. Nobody takes MDMA home.
Then the part that decides everything else. The Otago Daily Times put the cost at about NZ$15,000 a round, three rounds to a standard course, 54 hours of therapy, roughly NZ$45,000 in total. No public funding has been allocated.
The difference between approving a drug and approving two doctors is not pedantry. Approving a drug sets off a supply chain, a price negotiation and a funding decision. Approving two doctors sets off none of them.
Australia Ran This Experiment Two Years Ago
Australia rescheduled MDMA and psilocybin on 1 July 2023, and in doing so became the case study nobody covering New Zealand this week bothered to read.
The Australian numbers are not published on a dashboard. You have to ask for them. A freedom-of-information release to the Therapeutic Goods Administration put the count at 87 MDMA patients as of mid-September 2025, and a later TGA disclosure recorded 123 patients across 48 authorised prescribers by 31 December 2025. That is roughly two years of a live national scheme in a country of 27 million people.
Now the arithmetic nobody has run. Across the life of the Australian scheme, those 48 authorised prescribers average about 2.6 patients each. New Zealand has two of them.
Be honest about what that estimate can and cannot carry. Australian prescribers were authorised on a rolling basis, so the real per-prescriber, per-year rate is higher than a flat average implies. Wynn and Paterson are specialists who spent a year fighting for this and will almost certainly work harder at it than the Australian median. Push the figure as far as the evidence honestly allows and you still land somewhere between single digits and a few dozen New Zealanders in the first year.
Notice what is not constraining that number. Australia’s regulator has recorded no serious adverse events under the MDMA pathway. Safety is not the bottleneck here. Price and headcount are.
Nobody Has Said Who Pays
PTSD ruins lives and is difficult to treat. MDMA can be very effective at treating it through psychedelic-assisted therapy.
That is Associate Health Minister David Seymour, and it is a strong claim to make. A minister who believes it ought to be able to answer the obvious follow-up, which is who pays the NZ$45,000. Pharmac funds none of this. ACC has not been mentioned. The government took the announcement and left the invoice with the patient.
Our position, and it is not a knock on the therapy: the evidence is good enough that the funding silence is the scandal. The 2021 Phase 3 trial found 88% of participants improved significantly and 67% no longer met the diagnostic criteria, with a 2023 trial putting that second figure at 71.2%. If ministers believe those numbers, the honest response is a funding pathway. If they do not believe them, the honest response is to say that out loud. What is not defensible is banking the headline for a treatment the state has quietly priced beyond almost everyone it is meant to help.
The scale of that mismatch is hard to state precisely, which is its own small indictment. New Zealand’s only national estimate of PTSD prevalence comes from Te Rau Hinengaro, the mental health survey fielded in 2003 and 2004, which put 12-month prevalence at roughly 3% of the population. The country approved a treatment this week without a current count of the people who need it.
None of this makes New Zealand unusually reckless. The US Food and Drug Administration rejected Lykos Therapeutics’ MDMA application in August 2024, demanding another Phase 3 trial and flagging expectancy bias among participants who had used the drug recreationally, a problem a prescribing pathway routes around rather than solves. American policy has since swung hard the other way, with the White House fast-tracking psychedelic research in April.
New Zealand has picked a third position: the evidence is strong enough to permit, and not strong enough to pay for. So watch the funding decision, not the announcement. Australia’s 123 patients are what the permission is worth on its own.